| NCT03381170 |
An Extension of the TG1101â€RMS201 Trial |
https://ClinicalTrials.gov/show/NCT03381170 |
Active, not recruiting |
TG Therapeutics, Inc. |
2021-09-30 |
| NCT03401879 |
Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03401879 |
Recruiting |
Medical University of Vienna |
2020-12-31 |
| NCT03342638 |
Maximizing Outcome of Multiple Sclerosis Transplantation |
https://ClinicalTrials.gov/show/NCT03342638 |
Active, not recruiting |
Northwestern University |
2023-01-01 |
| NCT03283397 |
A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS |
https://ClinicalTrials.gov/show/NCT03283397 |
Recruiting |
Bosnalijek D.D |
2023-03-31 |
| NCT02515695 |
Phase I BP Interferon (IFN) Beta-001 |
https://ClinicalTrials.gov/show/NCT02515695 |
Completed |
Centre Hospitalier Universitaire Vaudois |
2005-07-31 |
| NCT03244696 |
Behavior and Activity Monitoring in MS |
https://ClinicalTrials.gov/show/NCT03244696 |
Recruiting |
Ohio State University |
2020-01-31 |
| NCT03177083 |
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy |
https://ClinicalTrials.gov/show/NCT03177083 |
Active, not recruiting |
Biogen |
2020-09-30 |
| NCT03091569 |
Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy |
https://ClinicalTrials.gov/show/NCT03091569 |
Completed |
Biogen |
2018-01-27 |
| NCT03085810 |
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT03085810 |
Active, not recruiting |
Hoffmann-La Roche |
2024-08-15 |
| NCT03060759 |
Light Therapy as Treatment for Fatigue in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03060759 |
Completed |
Massachusetts General Hospital |
2019-06-30 |
| NCT03029897 |
E-reporting of Adverse Drug Reactions by Patients in Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03029897 |
Completed |
University Hospital, Caen |
2019-04-24 |
| NCT03000647 |
Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03000647 |
Completed |
Instituto de Investigación Sanitaria de la Fundación Jiménez DÃaz |
2016-10-31 |
| NCT02988401 |
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02988401 |
Recruiting |
Johns Hopkins University |
2021-07-31 |
| NCT02975349 |
A Study of Efficacy and Safety of M2951 in Subjects With Relapsing Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02975349 |
Active, not recruiting |
EMD Serono |
2018-01-24 |
| NCT02939079 |
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT02939079 |
Completed |
Isfahan University of Medical Sciences |
2016-09-30 |
| NCT02914964 |
Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study |
https://ClinicalTrials.gov/show/NCT02914964 |
Active, not recruiting |
University of Iowa |
2019-10-31 |
| NCT02861014 |
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) |
https://ClinicalTrials.gov/show/NCT02861014 |
Active, not recruiting |
Hoffmann-La Roche |
2019-10-25 |
| NCT02782858 |
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS |
https://ClinicalTrials.gov/show/NCT02782858 |
Completed |
GeNeuro SA |
2017-08-31 |
| NCT02753088 |
Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02753088 |
Completed |
Biocad |
2015-11-30 |
| NCT02746744 |
RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. |
https://ClinicalTrials.gov/show/NCT02746744 |
Active, not recruiting |
Karolinska Institutet |
2021-05-31 |
| NCT02720107 |
Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01) |
https://ClinicalTrials.gov/show/NCT02720107 |
Completed |
Novartis |
2016-11-14 |
| NCT02696590 |
High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT02696590 |
Completed |
Isfahan University of Medical Sciences |
2015-11-30 |
| NCT02687919 |
Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02687919 |
Completed |
University of Iowa |
2014-09-30 |
| NCT02686788 |
TMP001 in Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02686788 |
Completed |
Fraunhofer Institute for Molecular Biology and Applied Ecology |
2018-04-30 |
| NCT02647502 |
A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02647502 |
Completed |
Johns Hopkins University |
2017-06-30 |
| NCT02637856 |
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) |
https://ClinicalTrials.gov/show/NCT02637856 |
Completed |
Genentech, Inc. |
2019-05-03 |
| NCT02634307 |
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1 |
https://ClinicalTrials.gov/show/NCT02634307 |
Active, not recruiting |
Biogen |
2021-05-17 |
| NCT02587065 |
Plegridy Satisfaction Study in Participants |
https://ClinicalTrials.gov/show/NCT02587065 |
Completed |
Biogen |
2017-10-02 |
| NCT02035514 |
Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02035514 |
Completed |
Germans Trias i Pujol Hospital |
2016-07-31 |
| NCT01093326 |
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01093326 |
Active, not recruiting |
Actelion |
2021-12-15 |
| NCT02555215 |
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT02555215 |
Completed |
Biogen |
2018-09-24 |
| NCT02545868 |
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02545868 |
Active, not recruiting |
Hoffmann-La Roche |
2017-02-14 |
| NCT02525874 |
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). |
https://ClinicalTrials.gov/show/NCT02525874 |
Completed |
Biogen |
2017-04-24 |
| NCT02517788 |
Phase I BP Interferon (IFN) Beta-004 |
https://ClinicalTrials.gov/show/NCT02517788 |
Completed |
Centre Hospitalier Universitaire Vaudois |
2006-07-31 |
| NCT02506751 |
Open-label Study of Liothyronine in MS |
https://ClinicalTrials.gov/show/NCT02506751 |
Completed |
Johns Hopkins University |
2017-09-18 |
| NCT02499900 |
Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® |
https://ClinicalTrials.gov/show/NCT02499900 |
Completed |
Teva Pharmaceutical Industries |
2017-01-10 |
| NCT02495766 |
Autologous Mesenchymal Stromal Cells for Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02495766 |
Completed |
Banc de Sang i Teixits |
2017-11-27 |
| NCT02493049 |
Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT02493049 |
Completed |
University of Calgary |
2019-02-28 |
| NCT02471560 |
Tecfidera and the Gut Microbiota |
https://ClinicalTrials.gov/show/NCT02471560 |
Completed |
Biogen |
2017-06-12 |
| NCT02461069 |
Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02461069 |
Completed |
University Hospital Muenster |
2018-01-24 |
| NCT02424396 |
Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02424396 |
Active, not recruiting |
Assistance Publique - Hôpitaux de Paris |
2019-10-11 |
| NCT02410200 |
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS |
https://ClinicalTrials.gov/show/NCT02410200 |
Completed |
Biogen |
2016-09-23 |
| NCT02398461 |
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse |
https://ClinicalTrials.gov/show/NCT02398461 |
Completed |
Acorda Therapeutics |
2017-09-30 |
| NCT02373098 |
Fingolimod Effect on Cytokine and Chemokine Levels |
https://ClinicalTrials.gov/show/NCT02373098 |
Completed |
Novartis |
2017-01-18 |
| NCT02315872 |
ACTH for Fatigue in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT02315872 |
Completed |
Providence Health & Services |
2017-06-20 |
| NCT02310048 |
Comparative Oral Bioavailability Study of MT-1303 |
https://ClinicalTrials.gov/show/NCT02310048 |
Completed |
Mitsubishi Tanabe Pharma Corporation |
2015-03-31 |
| NCT02293967 |
Mass Balance Study of MT-1303 |
https://ClinicalTrials.gov/show/NCT02293967 |
Completed |
Mitsubishi Tanabe Pharma Corporation |
2014-12-31 |
| NCT02283853 |
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT02283853 |
Active, not recruiting |
Biogen |
2025-09-08 |
| NCT02280876 |
Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT02280876 |
Completed |
Universidad Austral de Chile |
2015-02-28 |
| NCT02258217 |
Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) |
https://ClinicalTrials.gov/show/NCT02258217 |
Completed |
OhioHealth |
2016-06-24 |
| NCT02255656 |
Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 |
https://ClinicalTrials.gov/show/NCT02255656 |
Active, not recruiting |
Sanofi |
2020-06-30 |
| NCT03385356 |
Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03385356 |
Completed |
University Medical Centre Maribor |
2018-04-30 |
| NCT02212886 |
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS |
https://ClinicalTrials.gov/show/NCT02212886 |
Active, not recruiting |
Mapi Pharma Ltd. |
2017-05-31 |
| NCT02205489 |
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA |
https://ClinicalTrials.gov/show/NCT02205489 |
Completed |
Sanofi |
2016-04-30 |
| NCT02193217 |
A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303 |
https://ClinicalTrials.gov/show/NCT02193217 |
Completed |
Mitsubishi Tanabe Pharma Corporation |
2014-12-31 |
| NCT02142205 |
Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT02142205 |
Completed |
Biogen |
2013-12-31 |
| NCT02125604 |
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany |
https://ClinicalTrials.gov/show/NCT02125604 |
Completed |
Biogen |
2016-02-29 |
| NCT02117375 |
EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT02117375 |
Active, not recruiting |
Rennes University Hospital |
2022-04-30 |
| NCT02090413 |
Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02090413 |
Completed |
Biogen |
2015-02-28 |
| NCT02064816 |
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02064816 |
Completed |
Merck KGaA, Darmstadt, Germany |
2016-04-30 |
| NCT01317004 |
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change |
https://ClinicalTrials.gov/show/NCT01317004 |
Completed |
Novartis |
2014-06-30 |
| NCT01310166 |
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01310166 |
Completed |
Novartis |
2012-07-31 |
| NCT01307332 |
Advanced MRI Measures of Repair in Alemtuzumab Treated Patients |
https://ClinicalTrials.gov/show/NCT01307332 |
Completed |
University of British Columbia |
2018-09-28 |
| NCT01285401 |
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment |
https://ClinicalTrials.gov/show/NCT01285401 |
Completed |
Merck KGaA, Darmstadt, Germany |
2015-04-30 |
| NCT01279876 |
Melatonin in Relapsing-Remitting Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT01279876 |
Completed |
Tehran University of Medical Sciences |
2014-01-31 |
| NCT02040298 |
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT02040298 |
Completed |
University of California, San Francisco |
2015-09-30 |
| NCT02019550 |
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use |
https://ClinicalTrials.gov/show/NCT02019550 |
Completed |
EMD Serono |
2016-01-31 |
| NCT02010554 |
Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS |
https://ClinicalTrials.gov/show/NCT02010554 |
Completed |
University of Missouri, Kansas City |
2015-03-31 |
| NCT01925690 |
Development of a Motivational Intervention to Improve Treatment Adherence in MS |
https://ClinicalTrials.gov/show/NCT01925690 |
Completed |
University of Missouri, Kansas City |
2015-04-30 |
| NCT01917019 |
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01917019 |
Completed |
Biogen |
2015-10-31 |
| NCT01890655 |
Extension Study of MT-1303 |
https://ClinicalTrials.gov/show/NCT01890655 |
Completed |
Mitsubishi Tanabe Pharma Corporation |
2016-03-31 |
| NCT01884935 |
PK and PD Study of Natalizumab in Pediatric Subjects With RRMS |
https://ClinicalTrials.gov/show/NCT01884935 |
Completed |
Biogen |
2014-09-30 |
| NCT01874145 |
Safety and Tolerability of Glatiramer Acetate |
https://ClinicalTrials.gov/show/NCT01874145 |
Completed |
Teva Pharmaceutical Industries |
2014-04-30 |
| NCT01842191 |
Efficacy of Fish Oil in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01842191 |
Completed |
Coordinación de Investigación en Salud, Mexico |
2011-12-31 |
| NCT01838668 |
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT01838668 |
Completed |
Biogen |
2015-06-16 |
| NCT01808885 |
Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta. |
https://ClinicalTrials.gov/show/NCT01808885 |
Completed |
Hoffmann-La Roche |
2014-01-31 |
| NCT01805336 |
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality |
https://ClinicalTrials.gov/show/NCT01805336 |
Recruiting |
University Hospital, Caen |
2020-09-30 |
| NCT01791244 |
A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device |
https://ClinicalTrials.gov/show/NCT01791244 |
Completed |
Merck KGaA, Darmstadt, Germany |
2016-02-29 |
| NCT01772199 |
Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01772199 |
Completed |
GlaxoSmithKline |
2014-09-30 |
| NCT01742052 |
Dose-finding Study of MT-1303 |
https://ClinicalTrials.gov/show/NCT01742052 |
Completed |
Mitsubishi Tanabe Pharma Corporation |
2014-07-31 |
| NCT01738347 |
Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). |
https://ClinicalTrials.gov/show/NCT01738347 |
Completed |
GE Healthcare |
2016-05-31 |
| NCT01717664 |
Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT01717664 |
Completed |
RedHill Biopharma Limited |
2015-12-31 |
| NCT01707992 |
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT01707992 |
Completed |
Teva Pharmaceutical Industries |
2015-04-13 |
| NCT01667796 |
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health |
https://ClinicalTrials.gov/show/NCT01667796 |
Completed |
Johns Hopkins University |
2014-03-31 |
| NCT01591551 |
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness |
https://ClinicalTrials.gov/show/NCT01591551 |
Completed |
Cornerstone Health Care, PA |
2013-08-31 |
| NCT01564511 |
Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01564511 |
Completed |
Universita di Verona |
2012-02-29 |
| NCT01538355 |
A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01538355 |
Completed |
Charite University, Berlin, Germany |
2013-02-28 |
| NCT01534182 |
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) |
https://ClinicalTrials.gov/show/NCT01534182 |
Completed |
Novartis |
2013-06-30 |
| NCT01498887 |
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy |
https://ClinicalTrials.gov/show/NCT01498887 |
Completed |
Novartis |
2015-12-26 |
| NCT01497262 |
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01497262 |
Completed |
Novartis |
2014-04-30 |
| NCT01490502 |
Vitamin D Supplementation in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01490502 |
Active, not recruiting |
Johns Hopkins University |
2021-03-31 |
| NCT01489254 |
Efficacy and Safety of GTR in Comparison to Copaxone® |
https://ClinicalTrials.gov/show/NCT01489254 |
Completed |
Synthon BV |
2015-01-31 |
| NCT01470521 |
Worms for Immune Regulation of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01470521 |
Completed |
University of Nottingham |
2016-01-31 |
| NCT01466322 |
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers. |
https://ClinicalTrials.gov/show/NCT01466322 |
Completed |
GlaxoSmithKline |
2011-02-15 |
| NCT01466114 |
Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition |
https://ClinicalTrials.gov/show/NCT01466114 |
Recruiting |
University of California, Los Angeles |
2021-12-31 |
| NCT01462318 |
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01462318 |
Completed |
Biogen |
2016-01-31 |
| NCT01457924 |
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01457924 |
Completed |
GlaxoSmithKline |
2013-08-23 |
| NCT01450124 |
Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) |
https://ClinicalTrials.gov/show/NCT01450124 |
Completed |
Universitätsklinikum Hamburg-Eppendorf |
2014-12-31 |
| NCT01442233 |
Plasma Exchanges in Multiple Sclerosis (MS) Relapses |
https://ClinicalTrials.gov/show/NCT01442233 |
Completed |
University Hospital, Bordeaux |
2017-09-21 |
| NCT01433250 |
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01433250 |
Completed |
Novartis |
2014-06-30 |
| NCT01431937 |
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01431937 |
Completed |
GlaxoSmithKline |
2011-03-29 |
| NCT01428726 |
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01428726 |
Completed |
Neurotec Pharma |
2014-01-31 |
| NCT01424462 |
Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place. |
https://ClinicalTrials.gov/show/NCT01424462 |
Completed |
GlaxoSmithKline |
2010-07-06 |
| NCT01420055 |
Fingolimod -Response According to Coping - Evaluation |
https://ClinicalTrials.gov/show/NCT01420055 |
Completed |
Novartis |
2013-06-30 |
| NCT01417312 |
Metabolic Effects of a Green Tea Extract in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT01417312 |
Completed |
Charite University, Berlin, Germany |
2012-11-30 |
| NCT01416363 |
Healthy Volunteer Study Using 3 Different Formulations of Firategrast |
https://ClinicalTrials.gov/show/NCT01416363 |
Completed |
GlaxoSmithKline |
2011-09-17 |
| NCT01416155 |
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01416155 |
Completed |
Biogen |
2014-12-31 |
| NCT01414634 |
Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells |
https://ClinicalTrials.gov/show/NCT01414634 |
Completed |
Universitätsklinikum Hamburg-Eppendorf |
2012-10-31 |
| NCT01405820 |
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT01405820 |
Completed |
Biogen |
2014-04-30 |
| NCT01395316 |
Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01395316 |
Completed |
University of Chicago |
2015-10-31 |
| NCT01392872 |
Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant |
https://ClinicalTrials.gov/show/NCT01392872 |
Completed |
University Hospital, Clermont-Ferrand |
2016-01-31 |
| NCT01333501 |
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms |
https://ClinicalTrials.gov/show/NCT01333501 |
Completed |
Novartis |
2015-09-30 |
| NCT04280484 |
Acute Intermittent Hypoxia in Persons With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04280484 |
Completed |
Shirley Ryan AbilityLab |
2019-10-10 |
| NCT04261556 |
HD-tDCS to Enhance Cognitive Training in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04261556 |
Active, not recruiting |
University of Milano Bicocca |
2023-12-31 |
| NCT04233970 |
Development and Evaluation of a Web-based Programme on Relapse Management for People With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04233970 |
Recruiting |
Universitätsklinikum Hamburg-Eppendorf |
2020-12-31 |
| NCT04225312 |
Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04225312 |
Recruiting |
VU University Medical Center |
2023-01-02 |
| NCT04211740 |
Phase II Clinical Trial of OCH-NCNP1 |
https://ClinicalTrials.gov/show/NCT04211740 |
Enrolling by invitation |
National Center of Neurology and Psychiatry, Japan |
2020-09-30 |
| NCT04201470 |
Serum Neurofilaments and GFAP in Atypical Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04201470 |
Recruiting |
University Hospital, Montpellier |
2021-12-31 |
| NCT04121221 |
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS |
https://ClinicalTrials.gov/show/NCT04121221 |
Recruiting |
Mapi Pharma Ltd. |
2022-04-30 |
| NCT04115488 |
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® |
https://ClinicalTrials.gov/show/NCT04115488 |
Recruiting |
Polpharma Biologics S.A. |
2021-03-31 |
| NCT04075266 |
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04075266 |
Recruiting |
Hoffmann-La Roche |
2021-05-26 |
| NCT04073940 |
Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04073940 |
Recruiting |
University of Illinois at Urbana-Champaign |
2021-01-15 |
| NCT04047628 |
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) |
https://ClinicalTrials.gov/show/NCT04047628 |
Recruiting |
National Institute of Allergy and Infectious Diseases (NIAID) |
2025-12-31 |
| NCT03993171 |
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis (REPAIR-MS) |
https://ClinicalTrials.gov/show/NCT03993171 |
Recruiting |
Clene Nanomedicine |
2020-10-31 |
| NCT03979456 |
RItuximab Long-Term DOSE Trial in Multiple Sclerosis - RIDOSE-MS |
https://ClinicalTrials.gov/show/NCT03979456 |
Recruiting |
Karolinska Institutet |
2024-12-20 |
| NCT03958877 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03958877 |
Recruiting |
Biogen |
2023-03-31 |
| NCT03910738 |
TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03910738 |
Recruiting |
University Hospital, Strasbourg, France |
2023-05-31 |
| NCT03872583 |
Understanding Magnetic Resonance Imaging in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03872583 |
Recruiting |
Universitätsklinikum Hamburg-Eppendorf |
2021-03-31 |
| NCT03768648 |
Cognition and MRI Markers in MS Patients With Aubagio® Treatment |
https://ClinicalTrials.gov/show/NCT03768648 |
Recruiting |
University Hospital, Bordeaux |
2023-05-31 |
| NCT03758820 |
Behavior Cognitive Therapy on Fatigue Impact in MS Patients |
https://ClinicalTrials.gov/show/NCT03758820 |
Recruiting |
Réseau Sep Idf Ouest |
2019-03-31 |
| NCT03691766 |
Photobiomodulation Therapy in Persons With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03691766 |
Recruiting |
Marquette University |
2019-04-29 |
| NCT03689972 |
A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment |
https://ClinicalTrials.gov/show/NCT03689972 |
Active, not recruiting |
Biogen |
2021-01-15 |
| NCT03679806 |
Effects Aquatic Exercises on Balance and Hand Function in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03679806 |
Completed |
Dokuz Eylul University |
2016-07-31 |
| NCT03594487 |
Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03594487 |
Recruiting |
University of California, San Francisco |
2020-11-30 |
| NCT03551275 |
Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03551275 |
Active, not recruiting |
Biocad |
2019-03-31 |
| NCT03539094 |
Intermittent Fasting in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03539094 |
Recruiting |
Washington University School of Medicine |
2020-08-01 |
| NCT03536559 |
Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03536559 |
Recruiting |
Clene Nanomedicine |
2020-12-30 |
| NCT03535298 |
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS |
https://ClinicalTrials.gov/show/NCT03535298 |
Recruiting |
The Cleveland Clinic |
2022-12-31 |
| NCT03500328 |
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial |
https://ClinicalTrials.gov/show/NCT03500328 |
Recruiting |
Johns Hopkins University |
2023-08-01 |
| NCT03498131 |
Melatonin in Patients With Multiple Sclerosis (MS). |
https://ClinicalTrials.gov/show/NCT03498131 |
Recruiting |
Providence Health & Services |
2021-03-31 |
| NCT03471338 |
Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme |
https://ClinicalTrials.gov/show/NCT03471338 |
Recruiting |
University Hospital, Caen |
2020-12-31 |
| NCT01257958 |
Vitamin D Pilot Study in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01257958 |
Completed |
University of Wisconsin, Madison |
2000-02-29 |
| NCT01244139 |
Safety Study of BIIB033 in Subjects With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01244139 |
Completed |
Biogen |
2012-04-30 |
| NCT01225289 |
Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT01225289 |
Completed |
Tehran University of Medical Sciences |
2013-12-31 |
| NCT01201343 |
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT01201343 |
Completed |
Merck KGaA, Darmstadt, Germany |
2010-07-31 |
| NCT01185821 |
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01185821 |
Completed |
Novartis |
2016-10-10 |
| NCT01167426 |
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients |
https://ClinicalTrials.gov/show/NCT01167426 |
Completed |
Teva Pharmaceutical Industries |
2010-11-30 |
| NCT01156311 |
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01156311 |
Completed |
Biogen |
2012-03-31 |
| NCT01144052 |
Natalizumab De-escalation With Interferon Beta-1b |
https://ClinicalTrials.gov/show/NCT01144052 |
Completed |
Ospedale Civico, Lugano |
2011-11-30 |
| NCT01143441 |
Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT01143441 |
Completed |
National Institutes of Health Clinical Center (CC) |
2017-08-11 |
| NCT01142466 |
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone |
https://ClinicalTrials.gov/show/NCT01142466 |
Completed |
Merck KGaA, Darmstadt, Germany |
2009-12-31 |
| NCT01116427 |
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01116427 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-06-30 |
| NCT01111656 |
Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b |
https://ClinicalTrials.gov/show/NCT01111656 |
Completed |
University Hospital Inselspital, Berne |
2010-04-30 |
| NCT01097668 |
ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01097668 |
Completed |
Apitope Technology (Bristol) Ltd. |
2013-07-31 |
| NCT01081782 |
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01081782 |
Completed |
Ono Pharmaceutical Co. Ltd |
2011-12-31 |
| NCT01071083 |
Treatment Interruption of Natalizumab |
https://ClinicalTrials.gov/show/NCT01071083 |
Completed |
Biogen |
2011-11-30 |
| NCT01067521 |
A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo |
https://ClinicalTrials.gov/show/NCT01067521 |
Completed |
Teva Pharmaceutical Industries |
2012-05-08 |
| NCT01064401 |
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01064401 |
Completed |
Biogen |
2014-03-31 |
| NCT01051817 |
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler |
https://ClinicalTrials.gov/show/NCT01051817 |
Completed |
Novartis |
2012-04-30 |
| NCT01051349 |
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01051349 |
Completed |
Biogen |
2016-08-25 |
| NCT01040117 |
Sensori-motor Integration Training in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01040117 |
Completed |
Universita di Verona |
2011-10-31 |
| NCT01006265 |
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01006265 |
Completed |
Actelion |
2011-06-01 |
| NCT00947752 |
Safety of New Formulation of Glatiramer Acetate |
https://ClinicalTrials.gov/show/NCT00947752 |
Completed |
Teva Pharmaceutical Industries |
2009-09-30 |
| NCT03870763 |
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants |
https://ClinicalTrials.gov/show/NCT03870763 |
Recruiting |
Biogen |
2021-11-30 |
| NCT00942591 |
Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b |
https://ClinicalTrials.gov/show/NCT00942591 |
Completed |
University Hospital Inselspital, Berne |
2009-04-30 |
| NCT00930553 |
An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab |
https://ClinicalTrials.gov/show/NCT00930553 |
Completed |
Sanofi |
2016-02-29 |
| NCT00882999 |
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT00882999 |
Completed |
Eli Lilly and Company |
2011-02-28 |
| NCT00879658 |
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00879658 |
Completed |
Novartis |
2011-05-04 |
| NCT00871780 |
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients |
https://ClinicalTrials.gov/show/NCT00871780 |
Completed |
Biogen |
2012-07-31 |
| NCT00870740 |
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00870740 |
Completed |
Biogen |
2012-05-31 |
| NCT00869986 |
A Study for Patients With Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00869986 |
Completed |
Eli Lilly and Company |
2009-09-30 |
| NCT03846219 |
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) |
https://ClinicalTrials.gov/show/NCT03846219 |
Active, not recruiting |
Immunic AG |
2020-05-31 |
| NCT03093324 |
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 |
https://ClinicalTrials.gov/show/NCT03093324 |
Completed |
Biogen |
2019-06-27 |
| NCT01623596 |
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. |
https://ClinicalTrials.gov/show/NCT01623596 |
Completed |
Novartis |
2015-07-13 |
| NCT00835770 |
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT00835770 |
Completed |
Biogen |
2019-11-08 |
| NCT03610139 |
Longitudinal Effect of Vitamin D3 Replacement on Cognitive Performance and MRI Markers in Multiple Sclerosis Patients |
https://ClinicalTrials.gov/show/NCT03610139 |
Recruiting |
American University of Beirut Medical Center |
2020-10-31 |
| NCT02638038 |
This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years |
https://ClinicalTrials.gov/show/NCT02638038 |
Completed |
InteKrin Therapeutics, Inc. |
2016-12-12 |
| NCT01930708 |
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes |
https://ClinicalTrials.gov/show/NCT01930708 |
Completed |
Biogen |
2016-03-31 |
| NCT04002934 |
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT04002934 |
Recruiting |
University of California, San Francisco |
2021-02-15 |
| NCT02579681 |
Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012 |
https://ClinicalTrials.gov/show/NCT02579681 |
Completed |
Biogen |
2016-12-21 |
| NCT01705236 |
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® |
https://ClinicalTrials.gov/show/NCT01705236 |
Completed |
Novartis |
2019-02-18 |
| NCT03963375 |
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT03963375 |
Recruiting |
Washington University School of Medicine |
2023-06-30 |
| NCT00813969 |
Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS |
https://ClinicalTrials.gov/show/NCT00813969 |
Completed |
The Cleveland Clinic |
2014-01-31 |
| NCT00676715 |
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00676715 |
Active, not recruiting |
Genentech, Inc. |
2012-03-09 |
| NCT00668343 |
Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo |
https://ClinicalTrials.gov/show/NCT00668343 |
Completed |
Tehran University of Medical Sciences |
2008-03-31 |
| NCT00662649 |
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00662649 |
Completed |
Novartis |
2011-06-30 |
| NCT00645749 |
Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00645749 |
Completed |
University of Wisconsin, Madison |
2015-08-13 |
| NCT00641537 |
CLARITY Extension Study |
https://ClinicalTrials.gov/show/NCT00641537 |
Completed |
EMD Serono |
2011-12-31 |
| NCT00640328 |
Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients |
https://ClinicalTrials.gov/show/NCT00640328 |
Completed |
GlaxoSmithKline |
2010-05-31 |
| NCT00616187 |
Atorvastatin in Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00616187 |
Completed |
Charite University, Berlin, Germany |
2007-06-30 |
| NCT00594087 |
Eszopiclone for Improving Sleep in Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT00594087 |
Completed |
University of Vermont |
2008-05-31 |
| NCT00587691 |
Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00587691 |
Completed |
Opexa Therapeutics, Inc. |
2007-06-30 |
| NCT00559702 |
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT00559702 |
Completed |
Biogen |
2011-11-30 |
| NCT00548405 |
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two |
https://ClinicalTrials.gov/show/NCT00548405 |
Completed |
Sanofi |
2011-09-30 |
| NCT00534261 |
Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? |
https://ClinicalTrials.gov/show/NCT00534261 |
Completed |
Biogen |
NA |
| NCT00530348 |
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One |
https://ClinicalTrials.gov/show/NCT00530348 |
Completed |
Sanofi |
2011-04-30 |
| NCT00525668 |
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study) |
https://ClinicalTrials.gov/show/NCT00525668 |
Completed |
Charite University, Berlin, Germany |
2012-11-30 |
| NCT00509145 |
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT00509145 |
Completed |
Teva Pharmaceutical Industries |
2010-11-30 |
| NCT00493116 |
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta |
https://ClinicalTrials.gov/show/NCT00493116 |
Completed |
Biogen |
2009-12-31 |
| NCT00492765 |
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00492765 |
Completed |
Biogen |
2010-04-30 |
| NCT00492466 |
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies |
https://ClinicalTrials.gov/show/NCT00492466 |
Completed |
Biogen |
2006-08-31 |
| NCT00459667 |
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose |
https://ClinicalTrials.gov/show/NCT00459667 |
Completed |
Bayer |
2008-03-31 |
| NCT00451451 |
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00451451 |
Completed |
Biogen |
2011-08-31 |
| NCT00451204 |
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT00451204 |
Completed |
University of California, Los Angeles |
2014-07-31 |
| NCT00441103 |
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00441103 |
Completed |
Merck KGaA, Darmstadt, Germany |
2008-11-30 |
| NCT00428584 |
RNF and Betaseron® Tolerability Study |
https://ClinicalTrials.gov/show/NCT00428584 |
Completed |
EMD Serono |
2007-11-30 |
| NCT00420212 |
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00420212 |
Completed |
Biogen |
2011-02-28 |
| NCT00395317 |
Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT00395317 |
Completed |
GlaxoSmithKline |
2009-08-31 |
| NCT00390221 |
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00390221 |
Completed |
Biogen |
2011-05-31 |
| NCT00382629 |
BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00382629 |
Completed |
Bayhill Therapeutics |
NA |
| NCT00367484 |
Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00367484 |
Completed |
Merck KGaA, Darmstadt, Germany |
2006-01-31 |
| NCT00360906 |
Omega-3 Fatty Acid Treatment in Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00360906 |
Completed |
Haukeland University Hospital |
NA |
| NCT00355134 |
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00355134 |
Completed |
Novartis |
2011-06-30 |
| NCT00349193 |
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod |
https://ClinicalTrials.gov/show/NCT00349193 |
Completed |
Teva Pharmaceutical Industries |
2006-06-30 |
| NCT00340834 |
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase |
https://ClinicalTrials.gov/show/NCT00340834 |
Completed |
Novartis |
2011-07-31 |
| NCT00337779 |
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). |
https://ClinicalTrials.gov/show/NCT00337779 |
Completed |
Teva Pharmaceutical Industries |
2008-10-31 |
| NCT00317941 |
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif |
https://ClinicalTrials.gov/show/NCT00317941 |
Completed |
Bayer |
2008-04-30 |
| NCT00315367 |
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties |
https://ClinicalTrials.gov/show/NCT00315367 |
Completed |
Neurognostics |
NA |
| NCT00306592 |
Natalizumab Re-Initiation of Dosing |
https://ClinicalTrials.gov/show/NCT00306592 |
Completed |
Biogen |
2007-12-31 |
| NCT00292266 |
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) |
https://ClinicalTrials.gov/show/NCT00292266 |
Completed |
EMD Serono |
2002-06-30 |
| NCT00292253 |
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects |
https://ClinicalTrials.gov/show/NCT00292253 |
Completed |
EMD Serono |
2002-12-31 |
| NCT00289978 |
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00289978 |
Completed |
Novartis |
2009-07-31 |
| NCT00288626 |
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study |
https://ClinicalTrials.gov/show/NCT00288626 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2015-11-30 |
| NCT00276341 |
Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00276341 |
Completed |
Ipsen |
NA |
| NCT00245622 |
Autologous T Cell Vaccine (TCV) for Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00245622 |
Completed |
Opexa Therapeutics, Inc. |
2008-09-30 |
| NCT00242177 |
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability |
https://ClinicalTrials.gov/show/NCT00242177 |
Completed |
University of Illinois at Chicago |
NA |
| NCT00235989 |
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00235989 |
Completed |
Bayer |
2008-01-31 |
| NCT00228397 |
Study Evaluating CCI-779 in Relapsing Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00228397 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
2005-11-30 |
| NCT00220779 |
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00220779 |
Completed |
Grifols Therapeutics LLC |
2005-02-28 |
| NCT00213135 |
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) |
https://ClinicalTrials.gov/show/NCT00213135 |
Completed |
EMD Serono |
2008-11-30 |
| NCT00211887 |
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx |
https://ClinicalTrials.gov/show/NCT00211887 |
Completed |
Icahn School of Medicine at Mount Sinai |
2012-04-30 |
| NCT00206648 |
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS |
https://ClinicalTrials.gov/show/NCT00206648 |
Completed |
Bayer |
NA |
| NCT00203073 |
A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis. |
https://ClinicalTrials.gov/show/NCT00203073 |
Completed |
Teva Pharmaceutical Industries |
2005-01-31 |
| NCT00203021 |
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness |
https://ClinicalTrials.gov/show/NCT00203021 |
Completed |
Teva Pharmaceutical Industries |
2018-02-28 |
| NCT00200655 |
Safety and Efficacy of Pravastatin in Relapsing-remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00200655 |
Completed |
Nantes University Hospital |
NA |
| NCT00168766 |
Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS |
https://ClinicalTrials.gov/show/NCT00168766 |
Completed |
Biogen |
2008-11-30 |
| NCT01767701 |
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT01767701 |
Completed |
Queen Mary University of London |
2014-09-30 |
| NCT00112034 |
AVONEX® Combination Trial - “ACT” |
https://ClinicalTrials.gov/show/NCT00112034 |
Completed |
Biogen |
2006-06-30 |
| NCT00099502 |
BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients |
https://ClinicalTrials.gov/show/NCT00099502 |
Completed |
Bayer |
NA |
| NCT00097760 |
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00097760 |
Completed |
Biogen |
2004-03-31 |
| NCT00097331 |
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00097331 |
Completed |
GlaxoSmithKline |
2006-07-31 |
| NCT00097188 |
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00097188 |
Completed |
Genentech, Inc. |
NA |
| NCT00078338 |
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00078338 |
Completed |
EMD Serono |
2006-11-28 |
| NCT00076934 |
Safety of RG2077 in Patients With Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00076934 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00071838 |
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00071838 |
Completed |
National Institutes of Health Clinical Center (CC) |
2007-10-04 |
| NCT00067327 |
Treatment of Multiple Sclerosis Using Over the Counter Inosine |
https://ClinicalTrials.gov/show/NCT00067327 |
Completed |
National Center for Complementary and Integrative Health (NCCIH) |
NA |
| NCT00050778 |
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00050778 |
Completed |
Sanofi |
2007-09-30 |
| NCT00030966 |
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00030966 |
Completed |
Biogen |
2005-04-30 |
| NCT00027300 |
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis |
https://ClinicalTrials.gov/show/NCT00027300 |
Completed |
Biogen |
2004-11-30 |
| NCT00837785 |
A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS |
https://ClinicalTrials.gov/show/NCT00837785 |
Completed |
Biogen |
2009-10-31 |